Highlights

Most impactful activities

HIV Registry (NCT05231135)

This unique retrospective and prospective EHA LyG European registry was initiated in August 2021, but recruitment was stalled due to objections from the local Ethics Committee. These issues have been resolved and the recruitment started in the beginning of 2024.

This registry will create the largest repository of HIV lymphoma data for collaborative research. The objective is to analyze characteristics, type and toxicity of treatment, and outcomes of patients with HIV-related lymphoma.

Cantera lymphoma educational workshop

The 12th Cantera on the topic of ‘How the utilization of cellular therapy strategies looks like for lymphomas in 2024’ was held in Lecce, Italy, from May 15 to 17, 2024. It was coached by Prof Ana Sureda.

EHA-ESMO guideline partnership

The guidelines on HIV-related lymphomas and primary CNS lymphomas were published. Guidelines on other lymphoma types are being developed; some are expected to be published in 2025 and some in 2026.

All guidelines will undergo regular review and renewal.

EHA-ELI collaboration

A workshop on ‘Lymphoma of immunoprivileged sites’ was held in Stresa, Italy, on October 3–4, 2024.

European affairs

In collaboration with the EHA European Affairs Committee, the EHA LyG nominated experts to advise regulatory agencies on different items related to diagnosis and treatment of lymphoid malignancies.

Advances in activity

EHA-ESMO guideline partnership

The EHA LyG is working with the EHA Guidelines Committee and ESMO on developing consensus-based clinical practice guidelines for all lymphoma types. The new guidelines are expected to be published in HemaSphere in 2025 and 2026 and will undergo regular review and renewal.

Restructuring of the SWG in accordance with EHA recommendations

The EHA LyG Executive Board consists of nine members from different European countries, including a representative of Young EHA. A patient representative, a delegate of the Lymphoma Coalition, also actively participates in EB and group meetings.

We’ve reached a consensus on the rotation of board members that enables both innovation and continuity, and that preserves the national and gender balance.

In 2024, Prof Herve Tilly stepped down from the Executive Board and was replaced by Prof Marc Andre.

Collaboration with other SWGs

Our collaboration with the SWG on Immune Therapies and the SWG on Aging and Hematology resulted in grant approvals for research projects and educational meetings.

Top priorities for 2025

  • Jointly with ELI, to organize the next workshop on ‘Lymphoma in the mediastinum’ in Uppsala, Sweden, on September 18–19, 2025. The local organizer will be Dr Ingrid Glimelius.
  • Organize the EHA LyG session during the annual EHA Congress in Milan, with the topic: ‘Lymphoma treatment – When to start, when to stop and how to judge outcomes.’
  • Organize the 13th Cantera lymphoma educational workshop. This year’s topic will be: ‘The changing landscape in the management of patients with follicular and large B-cell lymphomas.’ The chair will be Prof Gilles Salles, and the course will be held in Lyon, France.
  • In collaboration with the SWG on Immune Therapies and the SWG on Aging and Hematology, to organize an educational meeting supported by the EHA in Krakow, Poland, in October 2026. The topic will be: ‘New standards in lymphoma treatment and immunotherapy in adult and elderly patients.’
Share